Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Multiple Myeloma × marizomib × Clear all

Phase

Status

Completed 4 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 37 Lenalidomide 17 Melphalan 16 Calcium Dobesilate 16 Bortezomib 15 Cyclophosphamide 9 pomalidomide 8 elotuzumab 7 pembrolizumab 6 fludarabine phosphate 6 carfilzomib 6 ixazomib 5 daratumumab 5 Filgrastim 5 selinexor 4 fludarabine 4 dexamethasone acetate 4 Thalidomide 4 Tacrolimus 4 Peripheral Blood Stem Cell Transplantation 4 dexamethasone 21-phosphate 3 Whole-Body Irradiation 3 Vorinostat 3 Nivolumab 3 Mycophenolic Acid 3 Magnetic Resonance Spectroscopy 3 Leukapheresis 3 Granulocyte Colony-Stimulating Factor 3 Ascorbic Acid 3 Arsenic Trioxide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05050305 2024-07-16

Marizomib Central Nervous System (CNS)

Dana-Farber Cancer Institute

Phase 2 Withdrawn

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡